Develops oral drug candidates for patients with urothelial cancers, achondroplasia and other genetically defined conditions.
10-K for FY2025, filed Mar 2, 2026We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted…View ↗
We are currently advancing oral dabogratinib in three Phase 2 trials for three outsized market indications: SURF303, evaluating the…View ↗
TYRA-430 was designed to be biased for FGFR4 and FGFR3 over the FGFR1 and FGFR2 isoforms specifically to address the FGF19 signaling…View ↗
TYRA-200 is an FGFR1/2/3 inhibitor designed to be active against nearly all of the clinically identified acquired resistant mutations that…View ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
−$51.1MView ↗
8-K, filed Nov 10, 2026
At 60 mg QD, oral dabogratinib demonstrated a 79% overall response rate (ORR) and 64% best overall response (BOR) complete response (CR)…View ↗
8-K, filed Mar 4, 2026
On March 4, 2026, Tyra Biosciences, Inc. (the “Company”) agreed to issue and sell 4,000,000 shares of common stock to a large investment…View ↗
Broader bladder-cancer focus
The earlier report centered the lead drug on metastatic urothelial cancer; the latest describes trials for low-grade upper-tract urothelial and non-muscle-invasive bladder cancers.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 2, 2026We are advancing multiple oncology product candidates toward the clinic, including our lead product candidate TYRA-300, an FGFR3 selective…View ↗
We are currently advancing oral dabogratinib in three Phase 2 trials for three outsized market indications: SURF303, evaluating the…View ↗
Achondroplasia advanced into clinical study
The earlier report described plans for studies of dabogratinib in pediatric achondroplasia; the latest describes an ongoing study in children with the condition.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 2, 2026Beyond oncology, FGFR3 is implicated in many developmental conditions, such as achondroplasia (ACH) and other skeletal dysplasias, due to…View ↗
BEACH301 for ACH: This study is an open-label, Phase 2 dose-escalation/dose-expansion trial evaluating oral dabogratinib at lower doses…View ↗
Competes with Urogen, Steba Biotech, Ferring, Sustained Therapeutics, Janssen Pharmaceutical, CG Oncology, BioMarin, Ascendis, BridgeBio, Bayer, Exelixis, Eli Lilly, Merck, BMS, CStone Pharmaceuticals, Blueprint Medicine, Everest Medicine, Abbisko Therapeutics, Incyte, and Taiho Oncology
10-K for FY2025, filed Mar 2, 2026For oral dabogratinib in LG-UTUC, the only agent commercially available is Urogen’s Jelmyto, a hydrogel reformulation of mitomycin C, which…View ↗
Loading...